Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 resistance pathways to EDP-235.

Antiviral research - 1 Sept 2026

Wang Kevin, Gibbons Joyce Sweeney, Bisht Nalini, Reyes Archie C, Cressey Tessa N, Crepeau Miranda L, Balakrishnan Anand, Kelly Nicole M, Bai Tian, Lovett David H, Torres Yanagisawa Akari E, Caccin Farah N M, Rhodin Michael H J, Iketani Sho

Abstract excerpt

SARS-CoV-2 infections continue to frequently occur, and treatment options remain limited, emphasizing the need for additional development of therapeutics. Here, we have conducted resistance profiling of EDP-235, a next-generation coronavirus 3CLpro inhibitor in clinical development. High-throughput passaging for resistance resulted in 29 out of 180 replicates surviving at 256-fold the EC50. Sequencing of these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Mutation

Share to Organic Chemicals

Share to SARS-CoV-2

Source

Identifiers

PMID: 42508618
DOI: 10.1016/j.antiviral.2026.106493

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 resistance pathways to EDP-235.PMID 42508618Read ↗

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity Read ↗

Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main proteaseSemantic proximity Read ↗

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor <i>in vitro</i> and confer resistance to nirmatrelvirSemantic proximity Read ↗

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read ↗

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance.Semantic proximity Read ↗

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read ↗

Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsSemantic proximity Read ↗

Identification and characterization of a SARS-CoV-2 Mpro G23 deletion ensitrelvir-resistant mutant.Semantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.Semantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.